Full-Time

Associate Director

Portfolio Management, Dice

Updated on 9/10/2026

Deadline 9/25/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$122k - $212.8k/yr

Hopewell Township, NJ, USA

Hybrid

Hybrid work is required.

Bachelor's

Category
Project & Program Management (1)
Required Skills
Agile
Product Management
CRM
Risk Management
Data Analysis

Get referred to Johnson & Johnson

See people who can refer or advise you

Requirements
  • A Bachelor's degree in Technology, Business, Marketing, Operations, or a related field is required.
  • At least 8 years of experience in product development or management, preferably in healthcare or life sciences, is required.
  • At least 5 years of experience owning and driving a portfolio of multiple products or platforms, including creating and maintaining business-priority roadmaps and artifacts, strategy planning, and monitoring risks, is required.
  • Experience bringing together cross-functional partners in matrixed organizations, presenting ideas, influencing planned outcomes, exhibiting flexibility in changing environments, and leading execution in an agile delivery model is required.
  • Hands-on experience with customer relationship management systems, specifically Salesforce Life Sciences Cloud or Health Cloud, is required.
  • Experience forging strong, productive relationships with diverse stakeholders is required.
  • Strong written and verbal communication skills, including the ability to influence across all organizational levels and proactively communicate achievements, risks, and associated impacts, are required.
  • Strong organization and attention to detail are required.
  • The ability to lead others and take accountability for driving outcomes is required.
Responsibilities
  • Translate strategic technical priorities across Digital Innovations and Customer Experiences and Patient Engagement and Customer Solutions into a clear portfolio roadmap containing major initiatives, milestones, dependencies, and decision points.
  • Support leadership in evaluating whether current and proposed work aligns with business outcomes, operating priorities, and value expectations.
  • Facilitate portfolio planning cycles, including annual budget planning, quarterly roadmap reviews, ongoing budget and financial tracking, and ad hoc reprioritization as business needs evolve.
  • Identify overlaps, gaps, sequencing issues, and opportunities to rationalize or consolidate work across the portfolio.
  • Keep the artifacts needed for prioritization conversations live and up to date.
  • Establish, lead, and maintain portfolio governance forums, cadence, agendas, decision logs, and escalation pathways.
  • Ensure key decisions are documented, communicated, and followed through to closure.
  • Prepare leadership materials summarizing portfolio health, trade-offs, risks, dependencies, and recommendations.
  • Partner with Supplier Management and Operational Excellence and other team members so the portfolio roadmap reflects decisions and actions from centralized demand-intake forums.
  • Prepare artifacts and materials for prioritization conversations and support leadership in making informed trade-off decisions when demand exceeds capacity.
  • Maintain a prioritized portfolio backlog and ensure requestors understand status, next steps, and decision outcomes.
  • Track progress against portfolio milestones, commitments, dependencies, and expected outcomes.
  • Identify delivery concerns early and partner with initiative or submission owners to develop mitigation or recovery plans.
  • Ensure reporting is accurate, timely, and actionable for leadership and stakeholders.
  • Partner with Finance to provide transparency into spending and tracking against the budget for Digital Innovations and Customer Experiences platforms.
  • Establish and implement value-realization practices.
  • Maintain an integrated view of material portfolio risks, issues, assumptions, and dependencies.
  • Escalate risks and issues with clear impact statements, mitigation options, recommendations, and required decisions.
  • Assess change impacts across the portfolio when scope, timeline, funding, priority, or resource assumptions shift.
  • Build and maintain trusted relationships with business, technology, finance, and leadership stakeholders.
  • Ensure stakeholders share an understanding of portfolio priorities, progress, decisions, risks, and trade-offs.
  • Tailor communications for executive summaries, working-team updates, and decision-oriented briefings.
  • Promote transparency, accountability, and timely engagement across the portfolio ecosystem.
Desired Qualifications
  • SAFe agile certification is preferred.
  • Experience with specialty pharmacy and patient hub services is preferred.
  • Experience with pharmaceutical compliance standards and healthcare data privacy regulations is preferred.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Carvykti topped $1 billion annual sales in January 2026, strengthening oncology.
  • IMAAVY won FDA approval on August 24, 2026, expanding a second launch.
  • Q2 2026 sales rose 6.6% to $25.31 billion, and guidance increased.

What critics are saying

  • The July 2026 talc settlement covers only existing claims, leaving future lawsuits open.
  • CVS dropped Stelara from main formularies in May 2026, accelerating biosimilar pressure.
  • Carvykti’s FDA boxed warning and Legend partnership constrain multiple myeloma expansion.

What makes Johnson & Johnson unique

  • J&J spans Innovative Medicine and MedTech, reducing dependence on any single franchise.
  • Carvykti and IMAAVY show J&J still converts R&D into first-in-class approvals.
  • Its oncology and immunology franchises offset Stelara’s erosion.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-3%
Yahoo Finance
Sep 3rd, 2026
J&J rises 1% as AbbVie's myeloma drug shows 74% response rate

Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.

Yahoo Finance
Sep 1st, 2026
P&G commits $10B in dividends amid 2.8B productivity savings while J&J's 28.5% stock surge masks mid-2027 spinoff risk

Procter & Gamble's dividend strategy is outpacing Johnson & Johnson's despite J&J's stronger stock performance this year. J&J's forward annualised dividend of $5.36 exceeds P&G's $4.354, but its planned mid-2027 DePuy Synthes spinoff threatens its dividend streak. P&G CEO Shailesh Jejurikar committed $10 billion in dividends and $5 billion in buybacks for fiscal 2027, supported by $2.8 billion in productivity savings. The company returned over $15 billion to shareholders in fiscal 2026, including more than $10 billion in dividends. J&J's stock surged 28.5% year-to-date versus P&G's 1.3% gain, driven by strong product performance. However, the upcoming spinoff poses uncertainty, as similar corporate events have disrupted other companies' dividend streaks. P&G faces no such structural risk.

Yahoo Finance
Aug 29th, 2026
J&J stock surges 52.8% in a year, outpacing consumer staples sector with strong pharma growth

Johnson & Johnson has significantly outperformed the consumer staples sector, with shares rising 52.8% over the past 52 weeks compared to the State Street Consumer Staples Select Sector SPDR Fund's 6.5% gain. The New Brunswick-based healthcare giant, valued at $640.5 billion, has seen particularly strong momentum recently, climbing 16.1% over three months. The company's strong performance follows solid second-quarter results released on 15 July, where sales increased 6.6% year-over-year to $25.31 billion. Adjusted earnings per share of $2.90 exceeded market expectations. Johnson & Johnson raised its full-year guidance, projecting adjusted EPS of $11.58 and sales of $101.1 billion. The stock currently trades just 3.1% below its 52-week high of $276.47, reached on 19 August.

Yahoo Finance
Aug 29th, 2026
AbbVie vs. Johnson & Johnson: Which healthcare stock offers better value in 2026?

AbbVie and Johnson & Johnson present distinct investment profiles in the healthcare sector. AbbVie focuses on biopharmaceuticals in immunology, oncology, and aesthetics, reporting fiscal 2025 revenue of $61.2 billion, up 8.7% year-over-year. Net income reached $4.3 billion with a 7% margin. The company generated $17.8 billion in free cash flow despite a negative debt-to-equity ratio of -21x. Johnson & Johnson operates through Innovative Medicine and MedTech segments. Revenue hit $94.2 billion in fiscal 2025, rising 6%. Net income nearly doubled to $26.8 billion from $14.1 billion the previous year, yielding a 29% margin. Its Darzalex portfolio accounted for 15% of total revenue. AbbVie relies heavily on three wholesale distributors for US sales, creating concentration risk. Johnson & Johnson maintains broader distribution globally.

Yahoo Finance
Aug 28th, 2026
JNJ stock surges 54% as TREMFYA's $2B quarter offsets STELARA's biosimilar decline

Johnson & Johnson's stock surged 54% between late August 2025 and late August 2026, outpacing the S&P 500's 20.5% return. The driver was a product transition that management flagged seven months before the rally began. STELARA faced biosimilar competition and declined 43.2% by mid-2025. Management named TREMFYA as its replacement, targeting the same inflammatory bowel disease patients who comprised 70% of STELARA's prescriptions. TREMFYA grew 30.1% during the same period. By July 2026, TREMFYA posted its first $2 billion quarter with 71% growth, offsetting STELARA's 55.7% decline. This product swap lifted the company's operational sales outlook to a $100.6 billion midpoint, demonstrating revenue durability despite losing a major franchise.